Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicentre, Open Label Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia

NCT04230239 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT04230239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04230239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicentre, Open Label Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
Lead sponsor
PETHEMA Foundation
Phase
Phase 2
Overall status
Completed
Start date
December 26, 2019
Completion date
August 11, 2021
Enrollment
59 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed secondary or high risk aml